FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kelly Thomas Patrick						2. Issuer Name and Ticker or Trading Symbol Deciphera Pharmaceuticals, Inc. [NA]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O DECIPHERA PHARMACEUTICALS, INC.				C.		3. Date of Earliest Transaction (Month/Day/Year) 06/11/2024								V	Officer (give title below) Chief Financial Officer			specify	
200 SMITH STREET				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person						
(Street) WALTHAM MA 02451 (City) (State) (Zip)														V	_	ed by Mor		One Repo	I
				R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Та	ble I - Nor	n-Deri	ivativ	ve Se	cur	ities Ac	quired,	Dis	posed c	of, or B	enefic	ially	Owned				
1. Title of Security (Instr. 3) 2. T				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			and Securitie Beneficia Owned F		lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) (D)	or Pri	ice	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)
Common	Stock			06/1	06/11/2024				A ⁽¹⁾		34,15	57	1	(1)	114,507		D		
Common	Stock			06/1	11/2024				D ⁽²⁾		72,02	.9 I)	(3)	42,478			D	
Common Stock 06/1				11/2024				U ⁽²⁾		42,47	'8 I		(4)				D		
1																			
			Table II -												Owned			<u>'</u>	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		(e.g.,		ction	5. N Deri Seci Acq or D of (E		uired, D s, option 6. Date Ex Expiration (Month/Da	ercisa Date	onverti	7. Title a of Secur Underlyi	nd Amou ities ng e Securi	unt	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Da	(e.g.,	puts 4. Transa Code (ction	5. N Deri Seci Acq or D of (E	umber of vative urities uired (A) bisposed D) (Instr.	6. Date Ex Expiration	ercisa Date y/Yea	onverti	7. Title a of Secur Underlyi Derivativ	nd Amou ities ng e Securi	unt lity lint per	8. Price of Derivative Security	derivative Securities Beneficia Owned Following	e s ally g	Ownership Form: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Da	(e.g.,	4. Transa Code (8)	action Instr.	5. Ni Deri Seci Acq or D of (I 3, 4	umber of vative urities uired (A) isposed (D) (Instr. and 5)	6. Date Ex. Expiration (Month/Da	ercisa Date y/Yea	able and arr)	7. Title a of Secur Underlyi Derivativ (Instr. 3	nd Amou ities ng re Securi and 4) Amou or Numb of Sha	ity int per ares	8. Price of Derivative Security	derivative Securities Beneficia Owned Following Reported Transacti	e s ally g	Ownership Form: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)
Derivative Security (Instr. 3) Stock Option (Right to	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Da	(e.g., late,	4. Transa Code (8)	action Instr.	5. Ni Deri Seci Acq or D of (I 3, 4	umber of vative urities uired (A) iisposed (b) (Instr. and 5)	6. Date Ex Expiration (Month/Da	ercisa Date y/Yea	able and ar)	7. Title a of Secur Underlyi Derivatii (Instr. 3	Amou or Numb of Sha	unt lity lint per ares	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Da	(e.g.,	4. Transa (Code (8)	action Instr.	5. Ni Deri Seci Acq or D of (I 3, 4	varrants umber of vative urities uired (A) isposed D) (Instr. and 5) (D)	e, option 6. Date Ex Expiration (Month/Da	ercisa Date y/Yea	converting able and arry Expiration late	7. Title a of Secur Underlyi Derivatii (Instr. 3	Amou or Numbof Shi	unt lity lity lity lity lity lity lity lit	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy) Stock Option (Right to Buy) Stock Option (Right to Buy)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) 06/11/2024 06/11/2024	3A. Deemed Execution Da	(e.g., ate, frame of the state)	puts 4. TransaCode (D(2) D(2)	action Instr.	5. Ni Deri Seci Acq or D of (I 3, 4	warrants umber of vative urities uiried (A) isposed)) (Instr. and 5) (D) 85,456	S, option 6. Date Exercisable Date Exercisable (5)	ercisa Date y/Yea	convertiable and arr) Expiration late (5)	7. Title a of Secur Underlyi Derivatii (Instr. 3 Title Common Stock	Amount of Shall Sh	unt lity lity lity lity lity lity lity lit	8. Price of Derivative Security (Instr. 5)	derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

\$15.48

\$15.92

06/11/2024

06/11/2024

Stock Option (Right to

Buy) Stock Option (Right to

1. Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not vet occurred.

(5)

(5)

65 900

69,100

D⁽²⁾

 $D^{(2)}$

Commor Stock

Stock

65,900

69,100

(5)

(5)

0

0

D

D

(5)

(5)

- 2. This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value \$0.01 per share (the "Common Stock") for a price per share of \$25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
- 3. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
- 4. Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding.
- 5. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

/s/ Jeffrey M. Held, Attorney- 06/11/2024 in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.